» Articles » PMID: 38223399

Increase in Invasive Group A Streptococcal Disease Among Australian Children Coinciding with Northern Hemisphere Surges

Abstract

Background: Increases in invasive group A streptococcal disease (iGAS) have recently been reported in multiple countries in the northern hemisphere, occurring during, and outside of, typical spring peaks. We report the epidemiology of iGAS among children in Australia from 1 July 2018 to 31 December 2022.

Methods: The Paediatric Active Enhanced Disease Surveillance (PAEDS) Network prospectively collected iGAS patient notifications for children and young people aged less than 18 years admitted to five major Australian paediatric hospitals in Victoria, Queensland, Western Australia and the Northern Territory. Patients were eligible for inclusion if they had GAS isolated from a normally sterile body site, or met clinical criteria for streptococcal toxic shock syndrome or necrotising fasciitis with GAS isolated from a non-sterile site. We report patients' clinical and demographic characteristics, and estimate minimum incidence rates.

Findings: We identified 280 paediatric iGAS patients, median age 4.5 years (interquartile range 1.4-6.4). We observed a pre-pandemic peak annualised incidence of 3.7 per 100,000 (95% CI 3.1-4.4) in the 3rd quarter of 2018, followed by a decline to less than 1.0 per 100,000 per quarter from 2020 to mid-2021. The annualised incidence increased sharply from mid-2022, peaking at 5.2 per 100,000 (95% CI 4.4-6.0) in the 3rd quarter and persisting into the 4th quarter (4.9 per 100,000, 95% CI 4.2-5.7). There were 3 attributable deaths and 84 (32%) patients had severe disease (overall case fatality rate 1%, 95% CI 0.2-3.3). Respiratory virus co-infection, positive in 57 of 119 patients tested, was associated with severe disease (RR 1.9, 95% CI 1.2-3.0). The most common -type was -1 (60 of 163 isolates that underwent typing, 37%), followed by 12 (18%).

Interpretation: Australia experienced an increase in the incidence of iGAS among children and young people in 2022 compared to pandemic years 2020-2021. This is similar to northern hemisphere observations, despite differences in seasons and circulating respiratory viruses. Outbreaks of iGAS continue to occur widely. This emphasises the unmet need for a vaccine to prevent significant morbidity associated with iGAS disease.

Funding: Murdoch Children's Research Institute funded open access publishing of this manuscript.

Citing Articles

Toxic Shock Syndrome Caused by Streptococcus dysgalactiae Subspecies equisimilis: A Report of a Rare Pediatric Case.

Koizumi N, Shikama Y, Ikebe T, Nagafuchi H, Imagawa T Cureus. 2025; 17(2):e78573.

PMID: 40062160 PMC: 11888792. DOI: 10.7759/cureus.78573.


Genomic interrogation of invasive group A (iGAS) epidemiology and COVID-19 impacts in Victoria, Australia: a 6-year retrospective study.

Morris J, Lacey J, Stevens K, Kumar L, Wilmot M, Strachan J Lancet Reg Health West Pac. 2025; 55:101467.

PMID: 39944419 PMC: 11814704. DOI: 10.1016/j.lanwpc.2025.101467.


The burden of group A (GAS) infections: The challenge continues in the twenty-first century.

Thacharodi A, Hassan S, Vithlani A, Ahmed T, Kavish S, Geli Blacknell N iScience. 2025; 28(1):111677.

PMID: 39877071 PMC: 11773489. DOI: 10.1016/j.isci.2024.111677.


Cardiac rupture and toxic shock syndrome by invasive group a Streptococcus in a Fontan patient with Asplenia syndrome.

Muraoka M, Tetsuhara K, Suzuki S, Yamamura K, Nakano T, Onoyama S J Cardiol Cases. 2025; 31(1):24-28.

PMID: 39839734 PMC: 11745787. DOI: 10.1016/j.jccase.2024.09.009.


Characterization of a novel SNP identified in Australian group A isolates derived from the M1 lineage.

Richter J, Cork A, Ong Y, Keller N, Hayes A, Schembri M mBio. 2024; 16(2):e0336624.

PMID: 39688411 PMC: 11796353. DOI: 10.1128/mbio.03366-24.


References
1.
Bagcchi S . Surge of invasive Group A streptococcus disease. Lancet Infect Dis. 2023; 23(3):284. DOI: 10.1016/S1473-3099(23)00043-9. View

2.
Lamagni T, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B . Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008; 46(7):2359-67. PMC: 2446932. DOI: 10.1128/JCM.00422-08. View

3.
Billard M, van de Ven P, Baraldi B, Kragten-Tabatabaie L, Bont L, Wildenbeest J . International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: Association with school closures. Influenza Other Respir Viruses. 2022; 16(5):926-936. PMC: 9343326. DOI: 10.1111/irv.12998. View

4.
Lamagni T, Guy R, Chand M, Henderson K, Chalker V, Lewis J . Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. Lancet Infect Dis. 2017; 18(2):180-187. DOI: 10.1016/S1473-3099(17)30693-X. View

5.
Moore H, Le H, Mace A, Blyth C, Yeoh D, Foley D . Interrupted time-series analysis showed unintended consequences of non-pharmaceutical interventions on pediatric hospital admissions. J Clin Epidemiol. 2021; 143:1-10. PMC: 8600916. DOI: 10.1016/j.jclinepi.2021.11.021. View